Ocular Therapeutix, Inc. OCUL
Set alert
At close · Oct 30
After hours · Oct 30, 6:43 PM ET
- YTD
- -42.59%
- 1 year
- -41.03%
- Open
- 7.27
- Prev close
- 7.31
- Mkt cap
- 1.53B
- Vol
- 2.63M
- Avg vol
- 3.06M
- EPS
- -1.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.93
- High
- 7.38
- Forward P/E
- -4.71
- Beta
- 0.99
- Short ratio
- 7.60
- Inst. own
- 95.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 8.89
- 200-d avg
- 9.14
- 1y target
- 25.45
News
3 days ago globenewswire.com
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…
1 week ago seekingalpha.com
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity
Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path,…
1 week ago seekingalpha.com
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
1 week ago marketbeat.com
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win
Ocular Therapeutix NASDAQ: OCUL is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration,…
-
1 week ago benzinga.com
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14
UBS analyst Alice Nettleton initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Buy rating and announces Price Target of $14.
3 weeks ago globenewswire.com
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted…
3 weeks ago benzinga.com
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
1 month ago globenewswire.com
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…
-
1 month ago benzinga.com
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
1 month ago marketbeat.com
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel…
1 month ago globenewswire.com
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $25 price target.
-
1 month ago benzinga.com
Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory…
1 month ago globenewswire.com
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence…
2 months ago globenewswire.com
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today…
2 months ago defenseworld.net
BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL
BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of…
2 months ago seekingalpha.com
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
2 months ago benzinga.com
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
2 months ago benzinga.com
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
2 months ago benzinga.com
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
2 months ago globenewswire.com
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina…
2 months ago defenseworld.net
California State Teachers Retirement System Increases Stock Position in Ocular Therapeutix, Inc. $OCUL
California State Teachers Retirement System increased its holdings in Ocular Therapeutix, Inc. (NASDAQ: OCUL) by 41.8% during the first quarter, according to its most recent filing with the…
2 months ago globenewswire.com
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina…
2 months ago seekingalpha.com
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat
Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI's annual dosing and clinic productivity…
3 months ago zacks.com
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.
-
3 months ago benzinga.com
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of…
3 months ago globenewswire.com
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
3 months ago marketbeat.com
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman,…
-
4 months ago benzinga.com
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Raises Price Target to $25
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $25.
-
4 months ago benzinga.com
Baird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $30
Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and raises the price target from $24 to $30.
4 months ago benzinga.com
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
-
4 months ago benzinga.com
Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety dataOcular to conduct interim SOL-R safety analysis in 4Q 2026 to reach…
-
4 months ago benzinga.com
Ocular Therapeutix Appoints Jason Robins CFO, Effective June 10
https://www.sec.gov/ix?doc=/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm
5 months ago benzinga.com
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.
8 months ago benzinga.com
GE Aerospace To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raised to $28, MDB cut to $260, RIOT cut to $23, DAVE raised to $295, NTST raised to $22, U raised to $19,…
8 months ago benzinga.com
Gold Down 3%; Medtronic Earnings Top Views
Gold Down 3%; Medtronic Earnings Top Views
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
8 months ago benzinga.com
Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the headline were updated in the story.) U.S. stock futures declined on Tuesday following Friday’s mixed…
-
8 months ago benzinga.com
Market-Moving News for February 17th
MDT: -5% | Medtronic Q3 Adj. EPS $1.36 Beats $1.33 Estimate, Sales $9.017B Beat $8.905B Estimate OBAI: 200% | TG-17 Announced Corporate Name Change To Our Bond; Trading Symbol On Nasdaq To
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 months ago benzinga.com
Why ZIM Integrated Shipping Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Why ZIM Integrated Shipping Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
9 months ago benzinga.com
Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday
Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
10 months ago benzinga.com
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session